secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001213900-25-084062
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea shareholders approve reverse split authorization (1:2–1:20) and 1.75M share increase for equity plan
--------------------------------------------------------------------------------

- Stockholders approved reverse stock split of common stock at ratio from 1:2 to 1:20, at Board discretion, valid through September 2026.
- Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares by 1.75M to 2,014,221 shares.
- Ratified CBIZ CPAs P.C. as independent auditor for FY2025 with 3.40M for, 39K against, 52K abstain.
- Re-elected Alfred Novak (1.31M for) and Simon Dumesnil (1.29M for) as Class II directors, terms expiring 2028.
- Quorum of 3.5M of 7.4M outstanding shares represented at the meeting; no other business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025084062/0001213900-25-084062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025084062/ea0255742-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-084062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer